

Epigenomics: Genome-Wide Study of Methylation Phenomena

K. L. Novik¹*, I. Nimmrich², B. Genc², S. Maier²,
C. Piepenbrock², A. Olek² and S. Beck¹

¹Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge CB10 1SA, UK

²Epigenomics AG, Kastanienallee 24, 10435 Berlin, Germany

Abstract

Epigenetics is one of the key areas of future research that can elucidate how genomes work. It combines genetics and the environment to address complex biological systems such as the plasticity of our genome. While all nucleated human cells carry the same genome, they express different genes at different times. Much of this is governed by epigenetic changes resulting in differential methylation of our genome – or different epigenomes. Individual studies over the past decades have already established the involvement of DNA methylation in imprinting, gene regulation, chromatin structure, genome stability and disease, especially cancer. Now, in the wake of the Human Genome Project (HGP), epigenetic phenomena can be studied genome-wide and are giving rise to a new field, epigenomics. Here, we review the current and future potential of this field and introduce the pilot study towards the Human Epigenome Project (HEP).

Introduction

The field of epigenetics is enjoying a meteoric rise from the euphoria surrounding the human genome project. The free availability and subsequent publication of the human draft sequence generated the essential foundation from which to explore the greater genetic complexities of life (IHGSC, 2001). Attention has now turned from the identification of genes to the expression and function of genes; epigenetics must surely hold one of the master keys to unlock and understand the mechanisms governing these vital processes.

Conrad Waddington suggested the phrase “epigenetics” in 1942, to describe the “study of the processes by which genotype gives rise to phenotype” (reviewed by Wu and Morris, 2001). The definition has evolved over the years to keep pace with the ever-expanding knowledge, and the most current classification of epigenetics would be: “a study of the changes in gene expression that are mitotically and/or meiotically heritable

and do not involve a change in the DNA sequence” (Wu and Morris, 2001). Epigenetic mechanisms are responsible for several phenomena including: X-inactivation – the random silencing of one of the X chromosomes in every normal somatic cell of female mammals (reviewed by Park and Kuroda, 2001) and genomic imprinting – the expression or repression of certain genes according to their parental origin (reviewed by Ferguson-Smith and Surani, 2001). From the latter half of the last century the simple addition of methyl groups, to DNA, was recognised as the main mechanism of epigenetics. It was soon accepted that DNA methylation could be variously associated with gene expression, genomic stability and disease (in particular the progression to malignancy), but proof remained elusive. The discovery of methylation-specific enzymes, within the last 20 years, provided much of that proof and established a direct link between DNA methylation, gene expression and changes in chromatin structure. The focus now is to understand global gene function and to probe the susceptibility to common diseases. Therefore, mechanisms that affect gene expression are at the forefront of current and future investigations. After years of struggling to be accepted as serious science, epigenetics - and in particular DNA methylation – has been drawn into the biological limelight. In order to reflect the fact that this branch of science is now being investigated genome-wide, it seems timely to add the term “epigenomics” to our scientific vocabulary.

Here we aim to provide an overview on DNA methylation, its function, and the potential association with malignancy and other common diseases. Furthermore, we provide an exploratory outlook of the novel field of epigenomics by introducing the pilot project that is spearheading the planned human epigenome project.

Cytosine methylation - the forgotten 5th base

The major target for methylation in the mammalian genome is cytosine; the enzymatic attachment of a methyl group to carbon-5 of the pyrimidine ring creates 5-methylcytosine (Doerfler, 1983; Santi *et al.*, 1983; Bird, 1992). This often forgotten 5th base of genomic DNA is indistinguishable from cytosine in its complementary base pairing with guanine. Furthermore, the majority of 5-methylcytosine (5-MeC) occurs in the context of the dinucleotide CpG, although CpNG, CC(a/t)GG, CpA and CpT can also be methylated at a very low frequency (Clark *et al.*, 1995; Woodcock *et al.*, 1997; Lorincz and Groudine, 2001). It is worth mentioning that in plants and filamentous fungi, cytosine methylation at non-CpG sites occurs much more frequently than in animals (Martienssen and Colot, 2001). Furthermore, in prokaryotes such as *E.coli* and *Agrobacterium tumefaciens* the N-6 position of adenine can become methylated (Kahng and Shapiro, 2001). Prokaryotic cytosine and adenine methylation can influence

*For correspondence. Email kln@sanger.ac.uk; Tel. +44(0)1223 494754; Fax. +44(0)1223 494919.

gene transcription, affect cell viability and also serve the restriction-modification systems that protect the bacterial host DNA from cleavage by specific endonucleases (Kahng and Shapiro, 2001).

CpG dinucleotides are non-randomly distributed across the mammalian genome; a phenomenon that appears to be driven, at least in part, by their methylation status. 5-MeC can spontaneously deaminate to thymine and, as a consequence, C to T transitions accumulate over evolutionary time (Duncan and Miller, 1980; Bird, 1987). By contrast, non-methylated cytosines deaminate to uracil, which is recognised as a “non-DNA” base and is promptly removed (Duncan and Miller, 1980; Bird, 1987). The interplay of CpG density and methylation is an interesting relationship and has created some fascinating genomic features. Three major targets for cytosine methylation are: CpG islands, G+C isochores and CpG hotspots.

CpG islands

The tendency of 5-MeC to spontaneous deamination means that most CpGs are present only once in every 80 dinucleotides, representing a one-fifth reduction of that predicted from the average base composition (40% G+C), and they are usually methylated (Subak-Sharpe *et al.*, 1966; Cooper and Krawczak, 1989). In contrast, a small proportion of total CpGs are clustered into “CpG islands”. These regions are on average 1-2 kb in length, with a CpG frequency close to that predicted from random base composition, and are unmethylated under normal circumstances (Bird *et al.*, 1985; Bird, 1987; Gardiner-Garden and Frommer, 1987, IHGS Consortium, 2001). The recent completion of the human genome draft sequence identified almost 29,000 potential CpG islands, with most chromosomes harbouring 5-15 islands per Mb (IHGS Consortium, 2001). There is a fairly good correlation between the number of CpG islands and gene density, with chromosome 19 having by far the highest average density of CpG islands (IHGS Consortium, 2001). CpG islands often encompass the promoters and early exons of genes (Bird, 1987; Gardiner-Garden and Frommer, 1987) and it is no surprise that these transcription-controlling regions should normally be unmethylated, when considering that methylation often leads to transcriptional silencing. Genes with tissue-specific expression patterns may be transcriptionally silent at given times but their associated CpG islands can remain unmethylated e.g. the human α -globin gene (Bird, 1987). It has been speculated that promoters, expressed in early development when methylation memory is most active, may create these unmethylated CpG islands (Bird, 2002). Furthermore, if transgene promoter function is impaired in transgenic mice then the associated CpG island becomes methylated (Macleod *et al.*, 1994). These results may be interpreted as the failure of transcription permitting *de novo* methylation (Bird, 2002). It is particularly noticeable during aging and the development of diseases, such as cancer (see below), that CpG island methylation increases (reviewed by Issa, 2000; Baylin and Herman, 2000). The mechanisms permitting CpG island *de novo* methylation remain elusive but may reflect cell-wide changes to the associated factors that regulate methylation (Jones and Laird, 1999).

G+C isochores

The human genome can be divided into large (>300 kb) mosaic structures, or isochores, which are compositionally fairly homogeneous and fall into distinct ranges of G+C content (for review see Bernardi, 2000; Bernardi, 2001). Five isochore families exist: L1 and L2 are G+C poor (~40%), H1 and H2 are G+C rich (45% and 50% respectively) and H3 is G+C very rich (53%). The recent completion of the draft human sequence (IHGSC, 2001) has provided a valuable resource for investigators to determine the precise isochore map of the entire genome (Pavliček *et al.*, 2002a). It has been demonstrated that the G+C content does equate to gene density, with H3 isochores containing the greatest number of genes, CpG islands and CG dinucleotides.

Some of the best-studied isochores in the human genome map to the major histocompatibility complex (MHC) on the short arm of chromosome 6. The MHC is divided into a number of different classes (see below) and the extended class II is an H2 isochore, class II is an L-family isochore and class III is an H3 isochore (Fukagawa *et al.*, 1995; Stephens *et al.*, 1999). Recently it has been shown that the MHC isochores are highly conserved between human and mouse, suggesting that strong selection is responsible for maintaining these structures (Pavliček *et al.*, 2002b). Furthermore, a definitive correlation has been found between the timing of DNA replication and different isochore families (Federico *et al.*, 1998; Federico *et al.*, 2000). Regions which are G+C rich, and therefore gene rich, replicate early in the cell cycle and condense late; the opposite is true for G+C poor regions. Precise switching of replication timing has been observed at the boundary between the isochores of the MHC classes II and III (Tenzen *et al.*, 1997). At the heart of replication timing lies chromatin, which controls the packaging and accessibility of the DNA. It has also been shown that covalent modifications of the exposed histone tails of chromatin (including methylation, acetylation and phosphorylation) may influence the interactions with accessory proteins and ultimately determine the transcriptional fate of the underlying DNA (for review see Jenuwein and Allis, 2001). As discussed below, methylation signals on DNA attract methyl-binding proteins (MBDs), recruit histone deacetylases (HDACs) and initiate local chromatin remodelling and condensation (reviewed by Robertson and Wolffe, 2000). Knowledge of methylation patterns across well-studied regions such as the MHC, would allow possible correlations between isochores, replication timing and temporal chromatin structure to be inferred; these all have major implications on the biological activity and stability of this region. Therefore, it is not surprising that the MHC has been chosen as the model system for such a study (see below).

CpG hotspots

CpG sites have been shown to act as hotspots for mutations. Up to 30 % of point mutations in the germline have been estimated to result from MeCpG \rightarrow TpG transitions caused by the spontaneous deamination of 5-methylcytosine (Cooper and Youssoufian, 1988). The p53

gene represents a well-studied example of this type of mutation. It has been shown that the CpG at codon 248 and two flanking CpGs of p53, were methylated in all tissues and cell lines studied and could therefore potentially act as mutational hotspots (Magewu and Jones, 1994). Also, approximately 50% of inactivating mutations in p53, occurring in colorectal cancer, are at CpG dinucleotides (Fearon and Jones, 1992).

Methylated cytosines can also serve to direct some carcinogens to CpG dinucleotides, which are the preferential targets for G to T transversion mutations in smoking-associated lung cancers (Yoon *et al.*, 2001). These point mutations are thought to result from polycyclic aromatic compounds such as benzo[a]pyrene and other bulky chemical carcinogens reacting with guanines that are flanked by 5-MeC (Pfeifer *et al.*, 2000). DNA methylation therefore promotes genetic alterations that may contribute towards carcinogenesis.

DNA methylating enzymes

Methyl groups are enzymatically added by DNA methyltransferases (DNMTs). Four mammalian DNMTs have been isolated and characterised to date: DNMT1 (Bestor *et al.*, 1988), DNMT2 (Yoder and Bestor, 1998), DNMT3A and DNMT3B (Okano *et al.*, 1998a). DNA methyltransferases have two well-characterised functions: the maintenance of methylation signals and *de novo* methylation. DNMT1 has been christened the global “maintenance methylase” because of an affinity for the hemi-methylated DNA that arises after DNA replication (Pradhan *et al.*, 1997; Pradhan *et al.*, 1999). This methylase ensures that the pre-replication methylation pattern is restored to the new DNA strand (Gruenbaum *et al.*, 1982; Stein *et al.*, 1982). Loss of DNMT1 is lethal; mouse embryos that are deficient in Dnmt1 die after gastrulation because of genome-wide demethylation (Li *et al.*, 1992). There is no direct evidence to exclude Dnmt1 from a role in *de novo* methylation and indeed methyltransferases do display overlapping functions (Bestor, 2000). Interestingly, the over-expression of DNMT1 leads to *de novo* methylation of endogenous CpG islands in cancer cell lines (Vertino *et al.*, 1996; Rhee *et al.*, 2000).

The role of DNMT2 is not yet fully understood and although it contains the conserved motifs characteristic of cytosine methyltransferases, it seems to lack such an activity *in vitro* (Okano *et al.*, 1998b). There is however some evidence for controlling of centromeric regions (Bestor, 2000).

DNMT3A and DNMT3B have *de novo* methylase activity and play a major role during early embryogenesis (Okano *et al.*, 1999). Shortly after fertilisation, the genome of the mouse zygote becomes demethylated (except for certain imprinted genes) by a poorly understood mechanism (reviewed by Razin and Cedar, 1993; Reik *et al.*, 2001). Genome-wide remethylation is orchestrated *de novo* by Dnmt3a and Dnmt3b at the time of implantation and is essential for normal mammalian development (Monk *et al.*, 1987; Razin and Cedar, 1993; Reik *et al.*, 2001). Mice that lack both Dnmt3a and Dnmt3b have abnormal morphology and die shortly after gastrulation (Okano *et*

al., 1999). Interestingly, despite the lack of *de novo* methylation these mutants still maintain the methylation patterns that were pre-existing, presumably as dnm1 remains functional (Okano *et al.*, 1999). Dnmt3a and Dnmt3b also exhibit some non-overlapping functions in development and have distinct expression patterns. Mice lacking either Dnmt3a or Dnmt3b display quite different developmental defects and ages at death (Okano *et al.*, 1999). Dnmt3b in particular is needed for the methylation of centromeric minor satellite repeats in the mouse. This function appears to be conserved evolutionarily; humans with the rare autosomal recessive ICF syndrome show hypomethylation of their pericentromeric heterochromatin and have been found to harbour mutations in DNMT3B (Jeanpierre, 1993; Hansen *et al.*, 1999; Okano *et al.*, 1999; Xu *et al.*, 1999).

It is interesting to note that clonal cell populations show heterogeneity in their DNA methylation patterns, maybe suggestive of variable fidelity in maintaining the original methylation signals (Pollack *et al.*, 1980; Silva *et al.*, 1993). As a consequence of these variable epigenetic signals, genotypically identical cells may have quite different phenotypes (Beck *et al.*, 1999). Furthermore, an enzyme with DNA demethylase activity has been reported recently but the biochemical characterisation is incomplete and the existence of the enzyme is still actively debated (Jost *et al.*, 1995; Bhattacharya *et al.*, 1999).

DNA methylation function

Two established functions of DNA methylation, that are not entirely mutually exclusive, involve the suppression of gene expression and the maintenance of genome integrity by the suppression of repetitive elements and heterochromatin.

Methylation modulates the interactions between DNA and proteins to bring about a change in chromatin structure that ultimately affects transcription (reviewed by Robertson and Wolffe, 2000; Jones and Takai, 2001). More often than not, methylation of the vertebrate genome results in transcriptional silencing. In some instances local methylation can directly interfere with the binding of transcription factors and thus prevent transcription (Iguchi-Arigo and Schaffner, 1989; Tate and Bird, 1993). Methylation of the regulatory sequences for transcription factors myc and AP-2 has been shown to inhibit their binding (Comb and Goodman, 1990; Prendergast and Ziff, 1991). Similarly, DNA methylation blocks the interaction between the zinc finger protein CTCF and the parentally imprinted Igf2/H19 insulator (Hark *et al.*, 2000; Holmgren *et al.*, 2001). However, many transcription factors are not fully influenced by the presence of 5-MeC in their recognition sequences or the sequences may not contain CpG sites at all. Sp1 controls the expression of many genes that have CpG rich promoter regions but binding is not influenced by the methylation of one CpG (Harrington *et al.*, 1988). The binding is only inhibited when the sequence CpCpG has both cytosines methylated (Clark *et al.*, 1997). Clearly an additional mechanism of methylation-mediated gene silencing was essential to account for global gene suppression.

In 1992, the first methyl-CpG binding protein, MECP2, was characterised (Lewis *et al.*, 1992). This protein has a great affinity for binding to methylated CpGs and then recruiting co-repressor complexes such as histone deacetylases (HDACs) to the site (reviewed by Robertson and Wolffe, 2000). MeCP2 recruits transcriptional co-repressors and the histone deacetylase, HDAC1, via the bridging protein Sin3 (Jones *et al.*, 1998; Nan *et al.*, 1998). HDACs deacetylate lysine residues on the histone tails, thus facilitating the interaction with neighbouring histones and the formation of a dense-packed chromatin structure that is repressive to gene expression. Additional methyl binding proteins (MBDs) have been identified over the last few years and have been called MBD 1-4 (Hendrich and Bird, 1998; reviewed by Wade, 2001). It is not yet clear whether hypoacetylation or methylation is the crucial step for gene silencing. Methylation induced gene silencing is prevented by treating cells with trichostatin A (TSA), a histone deacetylase inhibitor (Kass *et al.*, 1997). However, in oestrogen receptor (ER) negative breast cancer cells, re-expression of the receptor is permissible only by synergistic inhibition of DNA methylation and histone deacetylation (Yang *et al.*, 2000; Yang *et al.*, 2001). As well as acetylation, histone tails can also be modified by methylation and phosphorylation (reviewed by Jenuwein and Allis, 2001). It was recently shown that the methylation of histones could control DNA methylation in the filamentous fungus *Neurospora crassa* (Tamaru and Selker, 2001). Evidence suggests that the methylation of lysine 9 of histone H3 is needed for the active recruitment of DNMTs in *N. crassa* (Tamaru and Selker, 2001). Similarly, in a mammalian model, a methylation marker on Lys9 of H3 causes the recruitment of heterochromatin proteins and the subsequent repression of transcription (Bannister *et al.*, 2001). In both of these examples it would appear that methylation of histones could be the initiating event in changing the methylation status on the DNA level. Clearly, further studies are needed to unravel the complex interdependence of DNA methylation and histone modification in the pathway leading to transcriptional repression.

Closer observation of the mammalian genomic distribution of 5-MeC, reveals that the vast majority resides within retotransposons; these repetitive sequences account for approximately 40% of the genome and are CpG rich (Yoder *et al.*, 1997; Colot and Rossignol, 1999). It has been proposed that DNA methylation evolved as a host-defense mechanism to silence the expression and thereby limit the rogue-integration of these repetitive elements into transcriptional units (Yoder *et al.*, 1997; Bestor, 1998). Expression of integrated repetitive elements, from their strong promoters, can result in the formation of aberrant transcripts from the targeted transcriptional unit, irrespective of the orientation of integration (Robertson and Wolffe, 2000). Furthermore, reduced methylation of repetitive elements can result in chromosomal instability. Embryonic stem (ES) cells that are homozygous mutant for DNMT1 show hypomethylation of their repetitive elements, which are subsequently transcribed (Walsh *et al.*, 1998). There is also a 10-fold increase in the rate of mutations, involving gene rearrangements, compared to

the wild type ES cells (Chen *et al.*, 1998). Pericentromeric heterochromatin is also heavily methylated under normal situations and this appears crucial to maintaining chromosome conformation and preventing aberrant recombination (Ehrlich, 2000). Hypomethylation of the centromeric heterochromatin of chromosomes 1 and 16 leads to a number of gross chromosomal abnormalities such as isochromosomes, translocations and whole-arm deletions (Ehrlich, 2000). DNA methylation may suppress homologous recombination by blocking recombination initiation sites or by condensing the chromatin structure (Robertson, 2001).

DNA methylation and cancer

It is some 15 years since DNA methylation in tumor cells was recognised as being significantly different to the situation in normal cells (Goelz *et al.*, 1985; Feinberg *et al.*, 1988). These methylation alterations are often the earliest and most frequent events known to occur in human cancers (Jones, 1986). At least three different mechanisms exist in which DNA methylation contributes to tumor formation: mutational hotspots at CpG positions (as discussed above), general hypomethylation of genomic DNA and inactivation of tumor suppressor genes by hypermethylation of CpG islands.

Hypomethylation

Tumor cells can display global hypomethylation of the genome. Interestingly, this decrease in genomic methylation can be detected very early in malignancy, even before tumor formation (Christman *et al.*, 1993; Pogribny *et al.*, 1997). Furthermore, hypomethylation of oncogenes can generate increased and inappropriate gene expression. This has been shown for *bcl-2* in lymphocytic leukemia (Hanada *et al.*, 1993) and *k-ras* in lung and colon carcinomas (Feinberg and Vogelstein, 1983). Other regions frequently hypomethylated in tumors are transposons and repetitive elements such as SINES (short interspersed nuclear elements) and LINES (long interspersed nuclear elements). In urothelial cell carcinomas, LINE-1 retrotransposons and HERV-K (human endogenous retrovirus) proviral DNA are strongly hypomethylated compared to the respective normal tissue and transcription of these elements was observed (Flori *et al.*, 1999). Several other studies have also demonstrated that repetitive elements show reduced methylation in tumors and that this effect correlates with the progression of disease (Qu *et al.*, 1999). Additionally, tumors with global hypomethylation frequently display centromeric rearrangements of chromosomes 1 and 16; these centromeres are particularly rich in heterochromatin that would be methylated under the normal situation (Qu *et al.*, 1999).

Hypermethylation

The most prominent alterations of DNA methylation in cancer involve hypermethylation of CpG islands that are

Table 1. Genes that are hypermethylated in different cancers.

Gene	Function	Reference
APC	Negative regulator of Wnt pathway	Hiltunen <i>et al.</i> , 1997
BRCA1	DNA damage repair	Esteller <i>et al.</i> 2000b
CDH1 (E-cadherin)	homotypic epithelial cell-cell adhesion	Yoshiura <i>et al.</i> 1995; Graff <i>et al.</i> , 1995
CDKN2A	cyclin dependent kinase inhibitor (p16)	Gonzalez-Zulueta <i>et al.</i> , 1995; Herman <i>et al.</i> , 1995
CDKN2B	cyclin dependent kinase inhibitor (p15)	Herman <i>et al.</i> , 1996a; Batova <i>et al.</i> , 1997
DAPK1	mediator of interferon-induced apoptosis	Katzenellenbogen <i>et al.</i> , 1999
ER	estrogen receptor	Ottaviano <i>et al.</i> , 1994; Issa <i>et al.</i> , 1994
GSTP1	prevention of oxidative damage	Lee <i>et al.</i> , 1997; Esteller <i>et al.</i> , 1998
hMLH1	DNA mismatch repair	Kane <i>et al.</i> , 1997; Herman <i>et al.</i> , 1998; Leung <i>et al.</i> , 1999
LKB1	serine/threonine kinase	Esteller <i>et al.</i> 2000a
O6-MGMT	repair of guanosine methyl adducts	Esteller <i>et al.</i> , 1999
RB1	cell cycle regulator	Sakai <i>et al.</i> , 1991
TIMP3	inhibitor of tissue metalloproteinases	Bachman <i>et al.</i> , 1999
TP73	tumor suppressor gene, p53-like	Corn <i>et al.</i> , 1999
VHL	promotes angiogenesis	Herman <i>et al.</i> , 1994

usually, but not exclusively, unmethylated in normal tissue. In tumors, CpG islands that span the promoter regions of certain genes are often methylated in contrast to the bulk DNA that is hypomethylated. This CpG hypermethylation in tumors is often inversely correlated with gene expression. Knudson's "two hit" hypothesis of tumor generation assumes that for full inactivation of a tumor suppressor gene, two independent inactivating events are required; one at each of the specific alleles (Knudson, 1971). Initially, such "hits" were thought to be only intragenic mutations and/or loss of chromosomal DNA (loss of heterozygosity or LOH). It is now well accepted that promoter CpG methylation and the subsequent transcriptional repression of tumor suppressor genes, can also act as one of Knudson's "hits" (reviewed by Jones and Laird, 1999; Baylin and Herman, 2000). In the last few years a number of genes that are silenced by promoter CpG hypermethylation, in different kinds of tumors, have been described. Table 1 provides a summary of the most important of these genes with their respective references. A prominent example is the gene CDKN2A, which encodes the cyclin-dependent kinase inhibitor p16-ink4A. As a "genomic gatekeeper", p16 is critical in the cyclinD-Rb pathway for maintaining the retinoblastoma gene (Rb) in its active state (Sherr, 1996). Hypermethylation of this gene is a common mechanism of inactivation in several types of human cancers (Gonzalez-Zulueta *et al.*, 1995; Herman *et al.*, 1995). Furthermore, the colon adenocarcinoma cell line HCT116 has a nonsense mutation in one allele and methylation of the promoter region in the other allele (Myohanen *et al.*, 1998). Direct evidence linking hypermethylation with aberrant cell growth has been shown for cancer cell lines harbouring a methylated p16 gene and subsequently treated with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza-CdR). The expression of p16 is restored and cellular growth is suppressed (Bender *et al.*, 1998). The mismatch repair gene hMLH1, is also methylated in a large number of tumors. This tumor suppressor gene is mutated in familial colon cancers that also display the "microsatellite instability" (MIN+) phenotype. In sporadic colon tumors, that also show the MIN+ phenotype, mutations of hMLH1 are surprisingly rare (Moslein *et al.*, 1996; Thibodeau *et al.*, 1996) but aberrant promoter hypermethylation is quite common

(Cunningham *et al.*, 1998). The addition of 5-Aza-CdR to colon cancer cell lines that have a hypermethylated hMLH1 gene, leads to a reduction of promoter methylation, reexpression of the gene and a partial abolition of the MIN+ phenotype (Herman *et al.*, 1998).

Hitherto, we have only considered the association between DNA hypermethylation in cancer and transcriptional silencing. For those genes lacking CpG islands, the methylation density within the gene structure may correlate with transcriptional activity. Furthermore, methylation of downstream CpG sites is often correlated with increased transcription (Chan *et al.*, 2000). In chronic myelogenous leukaemia (CML), a chromosomal translocation juxtaposes the ABL protooncogene coding region with the 5'-untranslated region of the BCR gene (reviewed by Laurent *et al.*, 2001). The BCR-ABL fusion protein is therefore expressed from the BCR promoter. One of the ABL promoters can become embedded within the fusion gene and may be transcribed normally. However, as the disease progresses the ABL promoter becomes heavily *de novo* methylated and thus silenced; the fusion gene appears to be relatively overexpressed in comparison (Zion *et al.*, 1994). A positive correlation between gene expression and *de novo* methylation has also been reported for exon 5 of PAX6 in colon and bladder cancer (Salem *et al.*, 2000).

Tumour classification by methylation patterns

Several groups have shown that tumour classes can be determined by microarray-based expression profiling. Golub and colleagues (Golub *et al.*, 1999) investigated the expression levels of some 6800 genes and discovered that the profiles of just 50 informative genes were sufficient to distinguish between acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Using a similar gene expression approach, subclasses of diffuse large B-cell lymphoma could be classified according to their differences in response to therapy and disease outcome (Alizadeh *et al.*, 2000).

A number of recent studies have also shown an association between the pattern of DNA methylation in a tumor cell and tumor development. Costello and colleagues

used restriction landmark genomic scanning to show that methylation patterns are tumour-type specific (Costello *et al.*, 2000). Highly characteristic DNA methylation patterns have been shown for breast cancer cell lines (Huang *et al.*, 1999). Unique hypermethylation profiles, in several types of cancer, have also been demonstrated for a limited number of genes (Eads *et al.*, 2000; Esteller *et al.*, 2001). Zion and colleagues showed that *de novo* methylation of the normal ABL promoter, embedded in the BCR-ABL fusion gene, could be used as a reliable marker for tracking the progression of CML (Zion *et al.*, 1994). As with mRNA expression profiles, genome-wide methylation patterns should represent a molecular fingerprint of cancer tissues; determination of susceptibility to malignancy and prediction of outcome may be feasible using methylation profiling.

Methods to assess genome-wide methylation status have often employed the digestion of genomic DNA with methylation-sensitive enzymes; this unfortunately limits the analysis to sites for which these specific enzymes are available (Liang *et al.*, 1998; Toyota *et al.*, 1999; Yan *et al.*, 2000). The methylation status of specific genes can be assessed by sodium bisulphite treatment of genomic DNA; bisulphite converts all unmethylated cytosines to uracil but methylated cytosines are unchanged (Hayatsu *et al.*, 1970; Hayatsu, 1976). Several methods may then be employed to distinguish between the resulting sequence variants; e.g. bisulphite sequencing (Frommer *et al.*, 1992), methylation-specific PCR (Herman *et al.*, 1996b) and 'MethylLight' PCR (Eads *et al.*, 2000). Some of these approaches have been applied to determining the methylation status of large patient populations (Eads *et al.*, 2000; Esteller *et al.*, 2001) but they cannot analyse many genes in parallel. Recently, two novel microarray-based assays have been introduced that can perform this parallel analysis (Gitan *et al.*, 2001; Adorjan *et al.*, 2002). In the assay described by Adorjan and colleagues, specific CpG positions are PCR amplified from bisulphite-treated genomic DNA. The resulting sequence differences, between originally methylated and unmethylated CpGs, are detected by hybridising the PCR products to oligonucleotides immobilised on a glass slide. These oligonucleotides detect the originally methylated (CG) or unmethylated (TG) form of the CpG. Figure 1 illustrates this novel assay. Using supervised and unsupervised learning algorithms to analyse the results, it was possible to distinguish between acute lymphoblastic leukaemia and acute myeloid leukaemia (Model *et al.*, 2001; Adorjan *et al.*, 2002). They could also differentiate between primary prostate carcinomas, primary clear-cell kidney carcinomas and their respective normal controls. Some 200 CpG dinucleotides, located in the regulatory regions of 50 genes, were evaluated for methylation status in this study (Adorjan *et al.*, 2002). This certainly demonstrates that the DNA methylation patterns of a cell can be used to monitor tumorigenesis and they may be of clinical value if the prognostic and predictive relevance can be extrapolated.

DNA methylation and non-cancerous diseases

The sinister partnership between methylation and cancer is extensively documented but it should not be forgotten

that abnormalities of the methylation pathway have also been linked with other human diseases. Genomic imprinting, which is not extensively discussed in this review, is intimately linked with DNA methylation. The best-characterised syndromes arising from defective imprinting are Beckwith-Wiedemann syndrome (BWS) and the Prader-Willi/Angelman syndromes (for reviews see Reik *et al.*, 1997; Nicholls *et al.*, 1998). ICF syndrome is another disorder associated with aberrant methylation and results from mutations in the *de novo* methylase, DNMT3B (Hansen *et al.*, 1999; Okano *et al.*, 1999; Xu *et al.*, 1999). Rett syndrome, an X-linked neurodevelopmental disorder that occurs almost exclusively in females, is caused by mutations in the methyl-CpG binding protein, MECP2 (Hagberg *et al.*, 1983; Amir *et al.*, 1999). Mutations in the X-linked ATRX gene change the methylation patterns of highly repetitive sequences and as a consequence cause a syndrome characterised by alpha-thalassaemia and mental retardation (Gibbons *et al.*, 2000). Fragile X syndrome is a common form of mental retardation, that is also X-linked, and caused by aberrations in the FMR1 gene (Kremer *et al.*, 1991; Oberle *et al.*, 1991). FMR1 has a polymorphic CGG repeat in the untranslated region of exon 1 that is prone to great expansion in fragile X patients. This expansion encourages *de novo* methylation of the repeat but unfortunately also methylates the promoter of FMR1 and therefore aberrantly silences the gene (Kremer *et al.*, 1991; Oberle *et al.*, 1991).

The diverse phenotypes of these disorders suggest that methylation-mediated gene regulation is a highly complex process. Is there any evidence to suggest that aberrant methylation may be contributing towards the aetiology of more common diseases, such as diabetes mellitus?

A role for DNA methylation in diabetes?

Diabetes mellitus is classified into two principal groups. Type-1 diabetes mellitus (or juvenile diabetes) involves the autoimmune destruction of pancreatic islet cells by circulating autoantibodies, leading to the consecutive failure of insulin secretion. Type-2 diabetes mellitus comprises a heterogeneous group of mild forms of diabetes and the most prominent feature is the insulin resistance of target tissues such as liver, adipose tissue and muscle. This resistance leads to reactive hyperinsulinism and overt diabetes develops when the pancreatic beta cells can no longer maintain the increased insulin demands. Patients with type-2 diabetes can be grouped, on the basis of body weight, into obese and non-obese subtypes; further subclassification based on circulating insulin levels and other laboratory parameters is currently not possible. Up to 85% of patients with type-2 diabetes are obese, most frequently with an abdominal distribution of fat and a high waist-to-hip ratio. Genetic predisposition is a major risk factor for developing type-2 diabetes. It has been suggested that polymorphisms in genes involved in insulin secretion and response might modify individual disease susceptibility. However, in large population based studies only a few polymorphisms in such genes could be shown to influence the incidence of diabetes (Altshuler *et al.*, 2000; Hara *et al.*, 2000; Rissanen *et al.*, 2000).




Figure 1. A novel microarray-based assay for analyzing DNA methylation (Adorjan *et al.*, 2002).

(a) Illustration of the principle of the assay. Bisulphite-treated genomic DNA is amplified and the resulting fluorescently labelled PCR products are hybridized to oligonucleotides immobilised on a glass slide. For every CpG position there is a corresponding pair of oligonucleotides: one specific for the CpG position in its methylated (CG) and one in its unmethylated state (TG).

(b) A scan image, in false colours, resulting from a hybridised glass slide. The intensities of two adjacent spots (one containing the oligonucleotide specific for CG and the other one for TG), allow calculation of the methylation rate at the corresponding CpG position.

Recent studies have shown that development of obesity and type-2 diabetes is associated with changes in the expression levels of several genes (Goldfine *et al.*, 1999; Smith *et al.*, 1999; Andreelli *et al.*, 2000; Huang *et al.*, 2000; Nikoulina *et al.*, 2000; Steppan *et al.*, 2001). In a mouse model of type-2 diabetes and obesity, progression from a lean state to obesity and overt hyperglycemia was associated with changes in gene expression inverse to those seen in adipocyte differentiation (Nadler *et al.*, 2000). In a similar study in humans, gene expression was analysed in omental fat samples taken from lean and obese nondiabetic subjects and obese type-2 diabetic patients (Corominola *et al.*, 2001). The authors identified some 2000 cDNAs that showed potential differential expression between each of these groups (Corominola *et al.*, 2001). Furthermore, the upregulation of several genes, in response to insulin, was completely abrogated in type-2 diabetic patients compared to control subjects, insulin-resistant nondiabetic obese patients, and hyperglycemic type-1 diabetic subjects (Ducluzeau *et al.*, 2001). Interestingly, several oral anti-diabetic agents have been shown to correct the altered gene expression found in animal models of type-2 diabetes (Maier *et al.*, 2000; Steppan *et al.*, 2001). As a major regulator of transcriptional activity, DNA methylation may also be involved in the expression differences observed in type-2 diabetes.

Changes in methylation patterns have been described for several genes examined during the differentiation of various cell types (Takei *et al.*, 1996; Tutt Landolfi *et al.*, 1997; Yokomori *et al.*, 1999; Rothenburg *et al.*, 2001). Furthermore, DNA methylation represents a stable cellular memory for the maintenance of expression patterns, and may contain more information about the differentiation state of a population than the gene expression patterns themselves. T helper-1 (Th1) and -2 (Th2) cells exhibit striking differences in their patterns of cytokine expression; the expression is maintained in quiescent Th1 and Th2 cells even in the absence of further stimulation. The persistence of these expression patterns is thought to be due to epigenetic changes in chromatin structure, locus accessibility and DNA methylation (Agarwal *et al.*, 1998; Rao *et al.*, 2000). Also, methylation patterns in the IFN- γ promoter exhibit long-term faithful inheritance in T cells and their progeny. The demethylated IFN- γ promoter is faithfully inherited following the withdrawal of T cell stimulation and the loss of detectable IFN- γ mRNA (Fitzpatrick *et al.*, 1999). There is evidence that this "DNA methylation memory" is also involved in maintaining the gene expression patterns associated with insulin resistance in type-2 diabetes. Prenatal glucose and insulin levels influence the risk of developing type-2 diabetes in later life, quite independent of the maternal type of diabetes and genetic predisposition (Dabelea *et al.*, 2000). This suggests the presence of a "cellular memory" in insulin target tissues such as adipose tissue, skeletal muscle and liver. Several glucose-metabolism genes have already been shown to exhibit differential DNA methylation in their promoters; GLUT4, the major glucose transporter in adipose and muscle tissues, and the mitochondrial uncoupling protein UCP2 are good examples (Yokomori *et al.*, 1999; Carretero *et al.*, 1998). Furthermore, recent

insights into the pathogenesis of transient neonatal diabetes or TND (a rare subtype of diabetes that is characterized by transient hyperglycemia in the neonatal period and a predisposition to diabetes in adult life), provide a link between methylation, gene dosage effects and diabetes. TND results when gene dosage is doubled for the chromosomal region 6q24. Paternal uniparental isodisomy, duplication of the 6q24 region and loss of methylation in this imprinted region, all result in phenotypically indistinguishable TND (Temple *et al.*, 2000).

In addition to the orchestrated DNA methylation changes during cellular differentiation and in response to external stimuli, random DNA methylation changes have been observed during the aging of different organisms (Post *et al.*, 1999; Tohgi *et al.*, 1999; Bornmann *et al.*, 2001). These age-related methylation changes are involved in the aetiology of a number of different diseases such as atherosclerosis and cancer. Type-2 diabetes is strongly age-related; the incidence is increased in older populations and the metabolic situation of individuals deteriorates over time. Both of these phenomena may be explained by inappropriate DNA methylation accumulating with increasing age.

The human epigenome project

Andrew Feinberg recently proposed the idea of the "methylome" – the complete set of DNA methylation modifications of a cell (Feinberg, 2001). He suggests that knowledge of the methylome will extend our understanding of the genome, development, disease, and may also define polymorphic variation in populations (Feinberg, 2001). The recent completion of the human genome draft sequence (IHGSC, 2001), followed closely by a whole genome map of single nucleotide polymorphisms (The International SNP Map Working Group, 2001), established a solid foundation for the Human Epigenome Project (HEP). The Human Epigenome Consortium (HEC) is a rapidly growing international collaboration aiming to gain more insight into development, disease susceptibility and genome stability, by identifying global patterns of methylation in the human genome (Beck *et al.*, 1999). As a pilot study, partners of this consortium (including the authors of this review) are mapping methylation sites across the human major histocompatibility complex (MHC). This region was chosen because it is associated with more diseases (including most if not all autoimmune diseases) than any other region in the human genome and has a complex and interesting biology.

The human major histocompatibility complex (MHC)

The MHC is located on chromosome 6 (6p21.3). This locus contains genes with a high diversity of function, many of which are involved in the innate and adaptive immune systems, and is one of the most gene-dense regions of the human genome (for review see Rhodes and Trowsdale, 1999). The MHC has been subdivided into 5 different classes based loosely on the functional characteristics of the genes. The complete sequence of a "virtual" MHC haplotype was published in 1999 and was found to span




Figure 2. Gene map of the human MHC. Genes are displayed in order from telomere to centromere but are not drawn to scale. Solid black boxes indicate the loci that are being investigated for MVPs in the human epigenome pilot project. {Ψ} indicates the presence of a pseudogene. The extended class I, telomeric of the classical class I, is not included in the pilot MHC project and is therefore excluded from this figure.

about 8 Mb (MHC sequencing consortium, 1999). For historical reasons, classes I, II and III formed the classical MHC but analysis of flanking regions revealed that class II could be extended towards the centromere and class I towards the telomere. These regions are now referred to as the extended class I and II. Figure 2 is a gene map of the MHC indicating the order of the classes, and the genes therein, and the relative size of each class. For the sake of clarity in this review, the telomeric extended class I has been omitted from Figure 2 but a complete list of genes within this class can be found at <http://www.sanger.ac.uk/HGP/Chr6>. There are currently some 240 identified gene loci and 160 pseudogenes in the MHC. Over 40% of these loci were located as a direct result of the sequencing effort.

A number of genes within class I of the MHC are members of the immunoglobulin superfamily (e.g. HLA-A, -B and -C). They encode specialised cell-surface molecules (the so-called MHC molecules) that present short fragments of mainly intracellular antigenic peptides to the T-cell receptor of cytotoxic T cells (for review see Monaco, 1992). The response of the T cell leads to the killing of the presenting cell. Class I genes are ubiquitously expressed on the surface of most nucleated cells. Additionally the class I harbours a plethora of pseudogenes.

The class II genes HLA-DP, -DQ and -DR, are also members of the immunoglobulin superfamily. The cell-surface molecules that they encode are expressed only on specialised antigen-presenting cells such as macrophages, B cells and some T cells. These cells have the ability to engulf and internalise exogenous antigen and the class II molecules then present the resulting peptides to the specific receptor of a helper T cell. An adaptive immune response is then elicited (for review see Pieters, 1997). Classical class I and II genes are extremely polymorphic to allow for the vast specificity to a wide range of antigens. Other class II genes encode subunits of the proteasome (PSMB9 and PSMB8) – a macromolecular complex that degrades proteins within the cytoplasm and produces peptides for presentation by class I molecules (Groettrup *et al.*, 1996). Also the ABC2 and 3 genes together encode a heterodimeric molecule which spans the membrane of the endoplasmic reticulum (ER) and transports antigenic peptides from the cytoplasm into the ER for peptide loading of free class I molecules (Kelly *et al.*, 1992). The extended class II region also harbours some quite interesting genes. TAPBP (tapasin) facilitates the loading of peptide onto class I molecules (Ortmann *et al.*, 1997) and the DAXX gene product acts as an effector in an apoptotic pathway (Chang *et al.*, 1998).

The class III region of the MHC is very gene-dense and its members have quite disparate functions. Many are involved in innate immune responses and inflammation. The gene products of C2, C4 and BF form part of the complement cascade that instigates phagocytosis and lysis of bacterially infected cells and initiates an inflammatory response. The genes that control inflammation are clustered at the telomeric end and include TNF, LTA, LTB, LST1 and IC7.

It was recently shown that the B and T cell receptors, which specifically recognise antigens presented by MHC molecules, have monoallelic expression and the choice of

allele is controlled by epigenetic mechanisms (reviewed by Rada and Ferguson-Smith, 2002). Although this finding does not affect the MHC directly, it does illustrate that epigenetics can influence the immune system.

Autoimmune diseases and the MHC

The majority of human autoimmune diseases have been associated with the MHC but for many the exact causes remain unknown. Autoimmunity involves the destruction of self-tissue and/or cells by the immune system and these diseases do not conform to simple mendelian genetics. They have very complex segregation patterns, cannot be attributed to single causal genes and are likely to involve a substantial environmental element(s). “Etiological mutations” or allelic variants of genes controlling the immune system, combined on a background of environmental factors such as age, race and sex, predispose individuals to particular autoimmune diseases (Vyse and Todd, 1996). Identifying the responsible alleles is extremely difficult because of the very small risks conferred by the individual variants; the allelic combinations impose the full risk. A “needle-in-a-haystack” approach has historically been taken to elucidate the causative genes of multifactorial diseases. Numerous genome linkage and association studies have consistently identified correlations between autoimmune disorders and the MHC (Vyse and Todd, 1996; Das *et al.*, 2000). Predisposition (and sometimes resistance) to insulin-dependent diabetes mellitus (type 1 diabetes), rheumatoid arthritis, celiac disease and multiple sclerosis, have all been associated with various alleles of the class II genes HLA-DQB1 and HLA-DRB1 (Vyse and Todd, 1996; Das *et al.*, 2000). Alleles of some class I genes (in particular HLA-Cw6 and HLA-B57) have been found to increase susceptibility to the inflammatory skin disease, psoriasis (Russell *et al.*, 1972; Trembath *et al.*, 1997; Jenisch *et al.*, 1998). Ankylosing spondylitis also has an association with a class I allele (HLA-B27) and the class III complement genes C4A and C2, are reported to affect susceptibility to systemic lupus erythematosus (Das *et al.*, 2000). It should be mentioned that the MHC genotype alone is not always sufficient to cause autoimmunity and a number of non-MHC genes have also been implicated in susceptibility (Wandstrat and Wakeland, 2001). The association of class I and II alleles is unsurprising, given that an autoimmune response involves the action of T-cells which in turn rely upon presentation of an antigen by MHC molecules. However, it remains unclear how the MHC molecules allow autoantigen to be presented and how the target organ specificity is determined. One theory is that negative selection of T-cells in the thymus becomes imprecise, perhaps due to structural changes in the MHC molecules, and autoreactive T-cells are allowed to flourish (Das *et al.*, 2000). It is possible that there is an epigenetic component to autoimmunity; regulation of MHC gene expression may play a role in producing the susceptibility to autoimmune diseases. It would therefore be interesting and justified to examine the CpG methylation status of MHC loci.

The human epigenome pilot project

The MHC epigenome pilot project, established by members of the HEC, is the first of its kind to investigate the methylome on a large scale (Beck *et al.*, 1999). The project aims to map methylation variable positions (MVPs) (Beck, 2001) across the MHC in both the normal and the disease situation. Some 130 MHC loci (excluding the extended class I loci) have been selected for this study. These loci have a high CpG content and are therefore likely to contain MVPs. Figure 2 shows the selected loci as solid black boxes. Two or three PCR amplicons will be generated per MHC loci, with priority given to promoter regions and early exons. Amplicons are made from bisulphite-treated genomic DNA and the PCR products will be directly sequenced (Frommer *et al.*, 1992). A number of different healthy tissues, cell lines and individuals are included in the study and their methylation status will be compared with the MHC reference sequence (MHC Sequencing Consortium, 1999). Psoriasis, an MHC-associated skin disorder (Russell *et al.*, 1972; Trembath *et al.*, 1997; Jenisch *et al.*, 1998), has been chosen as the model disease in this pilot project and possible epigenetic components will be investigated.

Knowledge of the methylation signals across the MHC will add to the established data regarding the genomics, biology, and disease association of this locus; indeed it will be one of the most thoroughly investigated regions of the human genome. Hitherto unknown correlations between genomics and epigenomics may be uncovered, and it should highlight the functional interrelationships of genes in health and disease.

Outlook and summary

For a cell and for an organism, control is everything. The genome and its set of genes, like a deck of cards, is identical for all cells in a body. It is played in a different way each time giving rise to the high variability in protein expression patterns that are tightly controlled by "rules". Since the human genome project has shown us the deck of cards, we race on to figure out the details of these "rules" and epigenetics will be one of the keys to understanding them.

DNA methylation is the prototypical epigenetic parameter and its general properties are so well suited for regulating genes that it is no surprise that evolution selected it for this purpose. DNA methylation affects gene transcription, is heritable across cell division and there are enzymes to actively maintain or change it depending on environmental influences. These are the prerequisites to making cellular differentiation work and to lock cells into different differentiated states. In this way, DNA methylation represents an entire level of cellular information on top of the DNA sequence and provides a link between genotype and phenotype. Most importantly, DNA methylation is technically accessible and lends itself to analysis on a genomic scale. Sequencing and microarray technologies allow us to create an epigenomic map or the DNA methylation blueprint of the epigenome. Changes in DNA methylation patterns can therefore be monitored and correlated with the silencing of genes and pathways,

imprinting of genes, environmental influences, effects of health and nutrition, age-related changes, and disease-specific alterations.

The human epigenome project has been proposed as a venture of a huge scale. To get the complete picture, it will be necessary to read the methylation state from the regulatory regions of all genes, in all major cell types, and in their diseased variants. This project is realistic using modern genomic throughput technologies. The Human Epigenome Consortium (HEC) has initiated this process with a targeted approach on the MHC region, one of the most gene-rich regions of the human genome. The results of this project will create a map that complements the results of other large-scale efforts that are linking our knowledge of gene sequence and cellular phenotypes: the DNA sequence, its variations (SNPs), the mRNA expression patterns, and proteomic analyses. The epigenome map – the DNA methylation blueprint – will lay the ground for understanding gene regulation and the intricate interactions between different genes in normal and disease situations. Not only will it offer new explanations for well-studied areas like cancer research, but it will also provide a basis for novel approaches to research on environmental effects, nutrition, and ageing. Furthermore, combined with other genomic technologies, the benefits for pharmaceutical research will be immediate; DNA methylation screening promises new epigenetic markers for disease states and new targets for drug development. Already, some medical applications based on DNA methylation research are emerging in diagnostics (Cairns *et al.*, 2001). Some companies are even trying to directly target the epigenomic machinery of cells with drugs, for the treatment of cancer; methyltransferase inhibitors (Besterman and McLeod, 2000; Lubbert, 2000) and deacetylase inhibitors (Munster *et al.*, 2001) are entering clinical trials. These first attempts are using drugs with global effects on cells but more refined approaches will become possible with accumulating knowledge in the new field of epigenomics.

Acknowledgements

This work was supported in part by a grant from the European Union (QRLT-1999-30417). KLN and SB are also supported by the Wellcome Trust.

References

- Adorjan, P., Distler, J., Lipscher, E., Model, F., Mueller, J., Pelet, C., Braun, A., Florl, A.R., Guetig, D., Grabs, G. et al. 2002. Tumour class prediction and discovery by microarray-based DNA methylation analysis. *Nucleic Acid Res.* 30: e21 pp9.
- Agarwal, S., and Rao, A. 1998. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. *Immunity.* 9: 765-775.
- Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J. Jr., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock,

- G., and Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Staudt, L.M., et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*. 403: 503-511.
- Altshuler, D., Hirschhorn, J.N., Klannemark, M., Lindgren, C.M., Vohl, M.C., Nemesh, J., Lane, C.R., Schaffner, S.F., Bolk, S., Brewer, C., Tuomi, T., Gaudet, D., Hudson, T.J., Daly, M., Groop, L., and Lander, E.S. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nature Genet.* 26:76-80.
- Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U., and Zoghbi, H.Y. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat. Genet.* 23: 185-188.
- Andreelli, F., Laville, M., Vega, N., Riou, J.P., and Vidal, H. 2000. Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependent) diabetes mellitus. *Diabetologia*. 43: 356-363.
- Bachman, K.E., Herman, J.G., Corn, P.G., Merlo, A., Costello, J.F., Cavenne, W.K., Baylin, S.B., and Graff, J.R. 1999. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. *Cancer Res.* 59: 798-802.
- Bannister, A.J., Zegerman, P., Partridge, J.F., Miska, E.A., Thomas, J.O., Allshire, R.C., and Kouzarides, T. 2001. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature*. 410: 120-124.
- Batova, A., Diccianni, M.B., Yu, J.C., Nobori, T., Link, M.P., Pullen, J., and Yu, A.L. 1997. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. *Cancer Res.* 57: 832-836.
- Baylin, S.B. and Herman, J.G. 2000. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. *Trends Genet.* 16: 168-174.
- Beck, S., Olek, A., and Walter, J. 1999. From genomics to epigenomics: a loftier view of life. *Nat. Biotechnol.* 17: 1144.
- Beck, S. 2001. Genome acrobatics: understanding complex genomes. *Drug Discov. Today*. 6: 1181-1182.
- Bender, C.M., Pao, M.M., Jones, P.A. 1998. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. *Cancer Res.* 58: 95-101.
- Bernardi, G. 2000. Isochores and the evolutionary genomics of vertebrates. *Gene*. 241: 3-17.
- Bernardi, G. 2001. Misunderstandings about isochores. Part 1. *Gene*. 276: 3-13.
- Besterman, J.M. and McLeod, R. 2000. Targeting gene regulators for cancer therapy: Antisense inhibitors provide new sites for invention. *Modern Drug Discovery*. April p. 53-58.
- Bestor, T., Laudano, A., Mattaliano, R., and Ingram, V. 1988. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. *J. Mol. Biol.* 203: 971-983.
- Bestor, T.H. 1998. The host defense function of genomic methylation patterns. *Novartis Found. Symp.* 214: 6-16, discussion 16-21, 46-50.
- Bestor, T.H. 2000. The DNA methyltransferases of mammals. *Hum. Mol. Genet.* 9: 2395-2402.
- Bhattacharya, S.K., Ramchandani, S., Cervoni, N., and Szyf, M. 1999. A mammalian protein with specific demethylase activity for mCpG DNA. *Nature*. 397: 579-583.
- Bird, A., Taggart, M., Frommer, M., Miller, O.J., and Macleod, D.A. 1985. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA. *Cell*. 40: 91-99.
- Bird, A.P. 1987. CpG islands as gene markers in the vertebrate nucleus. *Trends Genet.* 3: 342-347.
- Bird, A. 1992. The essentials of DNA methylation. *Cell*. 70: 5-8.
- Bird, A. 2002. DNA methylation patterns and epigenetic memory. *Genes and Dev.* 16: 6-21.
- Bornmann, D.M., Mathew, S., Alsrue, J., Herman, J.G., and Gabrielson, E. 2001. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. *Am. J. Pathol.* 159: 831-835.
- Cairns, P., Esteller, M., Herman, J.G., Schoenberg, M., Jeronimo, C., Sanchez-Cespedes, M., Chow, N.H., Grasso, M., Wu, L., Westra, W.B., and Sidransky, D. 2001. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. *Clin. Cancer Res.* 7: 2727-2730.
- Carretero, M.V., Torres, L., Latasa, U., Garcia-Trevijano, E.R., Prieto, J., Mato, J.M., and Avila, M.A. 1998. Transformed but not normal hepatocytes express UCP2. *FEBS Lett.* 439: 55-58.
- Chan, M.F., Liang, G., and Jones, P.A. 2000. Relationship between transcription and DNA methylation. *Curr. Top. Microbiol. Immunol.* 249: 75-86.
- Chang, H.Y., Nishitoh, H., Yang, X., Ichijo, H., and Baltimore, D. 1998. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adaptor protein Daxx. *Science*. 281: 1860-1863.
- Chen, R.Z., Pettersson, U., Beard, C., Jackson-Grusby, L., and Jaenisch, R. 1998. DNA hypomethylation leads to elevated mutation rates. *Nature*. 395: 89-93.
- Christman, J.K., Sheikhejad, G., Dizik, M., Abileah, S., and Wainfan, E. 1993. Reversibility of changes in nucleic acid methylation and gene expression induced in rat liver by severe dietary methyl deficiency. *Carcinogenesis*. 14: 551-557.
- Clark, S.J., Harrison, J., and Frommer, M. 1995. CpNpG methylation in mammalian cells. *Nat. Genet.* 10: 20-27.
- Clark, S.J., Harrison, J., and Molloy, P.L. 1997. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. *Gene*. 195: 67-71.
- Colot, V., and Rossignol, J.-L. 1999. Eukaryotic DNA methylation as an evolutionary device. *BioEssays*. 21: 402-411.
- Comb, M. and Goodman, H.M. 1990. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. *Nucleic Acids Res.* 18: 3975-3982.
- Cooper, D.N., and Youssoufian, H. 1988. The CpG

- dinucleotide and human genetic disease. *Hum. Genet.* 78: 151-155.
- Cooper, D.N., and Krawczak, M. 1989. Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes. *Hum. Genet.* 83: 181-188.
- Corn, P.G., Kuerbitz, S.J., van Noesel, M.M., Esteller, M., Compitello, N., Baylin, S.B., and Herman, J.G. 1999. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. *Cancer Res.* 59: 3352-3356.
- Corominola, H., Conner, L.J., Beavers, L.S., Gadsdi, R.A., Johnson, D., Caro, J.F., and Rafaeloff-Phail, R. 2001. Identification of novel genes differentially expressed in omental fat of obese subjects and obese type-2 diabetic patients. *Diabetes.* 50: 2822-2830.
- Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., Robertson, G.P., Gao, X., Wright, F.A., Feramisco, J.D., Peltomaki, P., Lang, J.C., Schuller, D.E., Yu, L., Bloomfield, C.D., Caligiuri, M.A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N.J., Zhang, X., O'Dorisio, M.S., Held, W.A., Cavenee, W.K., and Plass, C. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. *Nat. Genet.* 24: 132-138.
- Cunningham, J.M., Christensen, E.R., Tester, D.J., Kim, C.Y., Roche, P.C., Burgart, L.J., and Thibodeau, S.N. 1998. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res.* 58: 3455-3460.
- Dabelea, D., Hanson, R.L., Lindsay, R.S., Pettitt, D.J., Imperatore, G., Gabir, M.M., Roumain, J., Bennett, P.H., and Knowler, W.C. 2000. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. *Diabetes.* 49: 2208-2211.
- Das, P., Abraham, R., and David, C. 2000. HLA transgenic mice as models of human autoimmune diseases. *Rev. Immunogenet.* 2: 105-114.
- Doerfler W. 1983. DNA methylation and gene activity. *Annu. Rev. Biochem.* 52: 93-124.
- Ducruzeau, P.H., Perretti, N., Laville, M., Andreelli, F., Vega, N., Riou, J.P., and Vidal, H. 2001. Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. *Diabetes.* 50: 1134-1142.
- Duncan, B.K., and Miller, J.H. 1980. Mutagenic deamination of cytosine residues in DNA. *Nature.* 287: 560-561.
- Eads, C.A., Danenberg, K.D., Kawakami, K., Saltz, L.B., Blake, C., Shibata, D., Danenberg, P.V., and Laird, P.W. 2000. MethyLight: a high-throughput assay to measure DNA methylation. *Nucleic Acids Res.* 28: E32.
- Ehrlich, M. 2000. DNA methylation: normal development, inherited diseases and cancer. *J. Clin. Ligand Assay.* 23: 144-146.
- Esteller, M., Corn, P.G., Urena, J.M., Gabrielson, E., Baylin, S.B., and Herman, J.G. 1998. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. *Cancer Res.* 58: 4515-4518.
- Esteller, M., Hamilton, S.R., Burger, P.C., Baylin, S.B., and Herman, J.G. 1999. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. *Cancer Res.* 59, 793-797.
- Esteller, M., Avizienyte, E., Corn, P.G., Lothe, R.A., Baylin, S.B., Aaltonen, L.A., and Herman, J.G. 2000a. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. *Oncogene.* 19: 164-168.
- Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I.C., Repasky, E.A., Gabrielson, E., Schutte, M., Baylin, S.B., and Herman, J.G. 2000b. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. *J. Natl. Cancer Inst.* 92: 564-569.
- Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. 2001. A gene hypermethylation profile of human cancer. *Cancer Res.* 61: 3225-3229.
- Fearon, E.R., and Jones, P.A. 1992. Progressing towards a molecular description of colorectal cancer development. *FASEB J.* 6: 2783-2790.
- Federico, C., Saccone, S., and Bernardi, G. 1998. The gene-richest bands of human chromosomes replicate at the onset of the S-phase. *Cytogenet. Cell Genet.* 80: 83-88.
- Federico, C., Andreozzi, L., Saccone, S., and Bernardi, G. 2000. Gene density in the Giemsa bands of human chromosomes. *Chromosome Res.* 8: 737-746.
- Feinberg, A.P. and Vogelstein, B. 1983. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. *Nature.* 301: 89-92.
- Feinberg, A.P., Gehrke, C.W., Kuo, K.C., and Ehrlich, M. 1988. Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Res.* 48: 1159-1161.
- Feinberg, A.P. 2001. Methylation meets genomics. *Nature Genet.* 27: 9-10.
- Ferguson-Smith, A.C., and Surani, M.A. 2001. Imprinting and the epigenetic asymmetry between parental genomes. *Science.* 293: 1086-1089.
- Fitzpatrick, D.R., Shirley, K.M., and Kelso, A. 1999. Cutting edge: stable epigenetic inheritance of regional IFN-gamma promoter demethylation in CD44^{high}CD8⁺ T lymphocytes. *J. Immunol.* 162: 5053-5057.
- Flori, A.R., Lower, R., Schmitz-Drager, B.J., and Schulz, W.A. 1999. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. *Br. J. Cancer.* 80: 1312-1321.
- Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., and Paul, C.L. 1992. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl. Acad. Sci. USA.* 89: 1827-1831.
- Fukagawa, T., Sugaya, K., Matsumoto, K., Okumura, K., Ando, A., Inoko, H., and Ikemura, T. 1995. A boundary of long-range G + C% mosaic domains in the human MHC locus: pseudoautosomal boundary-like sequence exists near the boundary. *Genomics.* 25: 184-191.
- Gardiner-Garden, M. and Frommer, M. 1987. CpG islands in vertebrate genomes. *J. Mol. Biol.* 196: 261-282.
- Gibbons, R.J., McDowell, T.L., Raman, S., O'Rourke, D.M., Garrick, D., Ayyub, H., and Higgs, D.R. 2000. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. *Nature Genet.* 24: 368-371.
- Gitan, R.S., Shi, H., Chen, C-M., Yan, P.S., and Huang, T.

- H-M. 2001. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. *Genome Res.* 12: 158-164.
- Goelz, S.E., Vogelstein, B., Hamilton, S.R., and Feinberg, A.P. 1985. Hypomethylation of DNA from benign and malignant human colon neoplasms. *Science.* 228:187-190.
- Goldfine, I.D., Maddux, B.A., Youngren, J.F., Trischitta, V., and Frittitta, L. 1999. Role of PC-1 in the etiology of insulin resistance. *Ann. N.Y. Acad. Sci.* 892: 204-222.
- Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., Bloomfield, C.D., Lander, E.S. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science.* 286: 531-7.
- Gonzalez-Zulueta, M., Bender, C.M., Yang, A.S., Nguyen, T., Beart, R.W., Van Tornout, J.M., and Jones, P.A. 1995. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. *Cancer Res.* 55: 4531-4535.
- Graff, J.R., Herman, J.G., Lapidus, R.G., Chopra, H., Xu, R., Jarrard, D.F., Isaacs, W.B., Pitha, P.M., Davidson, N.E., and Baylin, S.B. 1995. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. *Cancer Res.* 55, 5195-5199.
- Groettrup, M., Soza, A., Kjucekhorn, U., and Kloetzel, P.M. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. *Immunol. Today.* 17: 425-435.
- Gruenbaum, Y., Cedar, H., Razin, A. 1982. Substrate and sequence specificity of a eukaryotic DNA methylase. *Nature.* 295: 620-622.
- Hagberg, B., Aicardi, J., Dias, K., and Ramos, O. 1983. A progressive syndrome of autism, dementia, ataxia and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. *Ann. Neurol.* 14: 471-479.
- Hanada, M., Delia, D., Aiello, A., Stadtmauer, E., and Reed, J.C. 1993. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. *Blood.* 82: 1820-1828.
- Hansen, R.S., Wijmenga, C., Luo, P., Stanek, A.M., Canfield, T.K., Weemaes, C.M., and Gartler, S.M. 1999. The DNMT3B DNA methyltransferase gene is mutated in the ICF Immunodeficiency syndrome. *Proc. Natl. Acad. Sci. USA.* 96: 14412-14417.
- Hara, K., Okada, T., Tobe, K., Yasuda, K., Mori, Y., Kadowaki, H., Hagura, R., Akanuma, Y., Kimura, S., Ito, C., and Kadowaki, T. 2000. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. *Biochem Biophys. Res. Commun.* 271: 212-216.
- Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Levorse, J.M., and Tilghman, S.M. 2000. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. *Nature.* 405: 486-489.
- Harrington, M.A., Jones, P.A., Imagawa, M., and Karin, M. 1988. Cytosine methylation does not affect binding of transcription factor Sp1. *Proc. Natl. Acad. Sci. USA.* 85: 2066-2070.
- Hayatsu, H., Wataya, Y., Kai, K., and Iida, S. 1970. Reaction of sodium bisulfite with uracil, cytosine and their derivatives. *Biochem.* 9: 2858-2866.
- Hayatsu, H. 1976. Bisulfite modification of nucleic acids and their constituents. In: *Progress in Nucleic Acid Research and Molecular Biology.* W.E. Cohen, ed. Academic Press, New York. 16: 75-124.
- Hendrich, B. and Bird, A. 1998. Identification and characterization of a family of mammalian methyl-CpG binding proteins. *Mol. Cell. Biol.* 18: 6538-6547.
- Herman, J.G., Latif, F., Weng, Y., Lerman, M.I., Zbar, B., Liu, S., Samid, D., Duan, D.S., Gnarr, J.R., and Linehan, W.M. 1994. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc. Natl. Acad. Sci. USA.* 91: 9700-9704.
- Herman, J.G., Merlo, A., Mao, L., Lapidus, R.G., Issa, J.P., Davidson, N.E., Sidransky, D., and Baylin, S.B. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. *Cancer Res.* 55: 4525-4530.
- Herman, J.G., Jen, J., Merlo, A., and Baylin, S.B. 1996a. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. *Cancer Research.* 56: 722-727.
- Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., and Baylin, S.B. 1996b. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. USA.* 93: 9821-9826.
- Herman, J.G., Umar, A., Polyak, K., Graff, J.R., Ahuja, N., Issa, J.P., Markowitz, S., Willson, J.K., Hamilton, S.R., Kinzler, K.W., Kane, M.F., Kolodner, R.D., Vogelstein, B., Kunkel, T.A., and Baylin, S.B. 1998. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA.* 95: 6870-6875.
- Hiltunen, M.O., Alhonen, L., Koistinaho, J., Myohanen, S., Paakkonen, M., Marin, S., Kosma, V.M., and Janne, J. 1997. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. *Int. J. Cancer.* 70: 644-648.
- Holmgren, C., Kanduri, C., Dell, G., Ward, A., Mukhopadhyay, R., Kanduri, M., Lobanenkov, V., and Ohlsson, R. 2001. CpG methylation regulates the Igf2/H19 insulator. *Curr. Biol.* 11: 1128-1130.
- Huang, T.H., Perry, M.R., and Laux, D.E. 1999. Methylation profiling of CpG islands in human breast cancer cells. *Hum. Mol. Genet.* 8: 459-470.
- Huang, X., Vaag, A., Hansson, M., Weng, J., Laurila, E., and Groop, L. 2000. Impaired insulin-stimulated expression of the glycogen synthase gene in skeletal muscle of type 2 diabetic patients is acquired rather than inherited. *J. Clin. Endocrinol. Metab.* 85: 1584-1590.
- Iguchi-Ariga, S.M., and Schaffner, W. 1989. CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. *Genes Dev.* 3:612-619.
- International Human Genome Sequencing Consortium (IHGSC). 2001. Initial sequencing and analysis of the human genome. *Nature.* 409: 745-964.
- Issa, J.P., Ottaviano, Y.L., Celano, P., Hamilton, S.R.,

- Davidson, N.E., and Baylin, S.B. 1994. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. *Nat. Genet.* 7: 536-540.
- Issa, J.P. 2000. CpG-island methylation in aging and cancer. *Curr. Top. Microbiol. Immunol.* 249: 101-118.
- Jeanpierre, M., Turleau, C., Aurias, A., Prieur, M., Ledest, F., Fischer, A., and Viegas-Pequignot, E. 1993. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. *Hum. Mol. Genet.* 2: 731-735.
- Jenisch, S., Henseler, T., Nair, R.P., Guo, S.W., Westphal, E., Stuart, P., Kronke, M., Voorhees, J.J., Christophers, E., and Elder, J.T. 1998. Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. *Am. J. Hum. Genet.* 63: 191-199.
- Jenuwein, T., and Allis, C.D. 2001. Translating the histone code. *Science.* 293: 1074-1080.
- Jones, P.A. 1986. DNA methylation and cancer. *Cancer Res.* 46: 461-466.
- Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., Strouboulis, J., and Wolffe, A.P. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. *Nat. Genet.* 19: 187-191.
- Jones, P.L. and Laird, P.W. 1999. Cancer epigenetics comes of age. *Nat Genet.* 21: 163-167.
- Jones, P.A., and Takai, D. 2001. The role of DNA methylation in mammalian epigenetics. *Science.* 293: 1068-1070.
- Jost, J.P., Siegmund, M., Sun, L., and Leung, R. 1995. Mechanisms of DNA demethylation in chicken embryos. Purification and properties of a 5-methylcytosine-DNA glycosylase. *J. Biol. Chem.* 270: 9734-9739.
- Kahng, L.S., and Shapiro, L. 2001. The CcrM DNA methyltransferase of *Agrobacterium tumefaciens* is essential and its activity is cell cycle regulated. *J. Bacteriol.* 183: 3065-3075.
- Kane, M.F., Loda, M., Gaida, G.M., Lipman, J., Mishra, R., Goldman, H., Jessup, J.M., and Kolodner, R. 1997. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. *Cancer Res.* 57: 808-811.
- Kass, S.U., Pruss, D., and Wolffe, A.P. 1997. How does DNA methylation repress transcription? *Trends Genet.* 13: 444-449.
- Katzenellenbogen, R.A., Baylin, S.B., and Herman, J.G. 1999. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. *Blood.* 93: 4347-4353.
- Kelly, A., Powis, S.H., Kerr, L.A., Mockridge, I., Elliott, T., Bastin, J., Uchanska-Ziegler, B., Ziegler, A., Trowsdale, J., and Townsend, A. 1992. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. *Nature.* 355: 641-644.
- Knudson, A.G. 1971. Mutation and cancer: statistical study of retinoblastoma. *Proc. Natl. Acad. Sci. USA.* 68: 820-823.
- Kremer, E.J., Pritchard, M., Lynch, M., Yu, S., Holman, K., Baker, E., Warren, S.T., Schlessinger, D., Sutherland, G.R., and Richards, R.I. 1991. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)_n. *Science.* 252: 1711-1714.
- Laurent, E., Talpaz, M., Kantarjian, H., and Kurzrock, R. 2001. The BCR gene and philadelphia chromosome-positive leukemogenesis. *Cancer Res.* 61: 2343-2355.
- Lee, W.H., Isaacs, W.B., Bova, G.S., and Nelson, W.G. 1997. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. *Cancer Epidemiol. Biomarkers Prev.* 6: 443-450.
- Leung, S.Y., Yuen, S.T., Chung, L.P., Chu, K.M., Chan, A.S., and Ho, J.C. 1999. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. *Cancer Res.* 59: 159-164.
- Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, I., Jeppesen, P., Klein, F., and Bird, A. 1992. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. *Cell.* 69: 905-914.
- Li, E., Bestor, T.H., and Jaenisch, R. 1992. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell.* 69: 915-926.
- Liang, G., Salem, C.E., Yu, M.C., Nguyen, H.D., Gonzales, F.A., Nguyen, T.T., Nichols, P.W., and Jones, P.A. 1998. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. *Genomics.* 53: 260-268.
- Lorincz, M.C., and Groudine, M. 2001. C^mC(a/t)GG methylation: A new epigenetic mark in mammalian DNA? *Proc. Natl. Acad. Sci. USA.* 98: 10034-10036.
- Lubbert, M. 2000. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. *Curr Top Microbiol. Immunol.* 249: 135-164.
- Macleod, D., Charlton, J., Mullins, J., and Bird, A.P. 1994. Sp1 sites in the mouse *aprt* gene promoter are required to prevent methylation of the CpG island. *Genes and Dev.* 8: 2282-2292.
- Magewu, A.N. and Jones, P.A. 1994. Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. *Mol. Cell Biol.* 14: 4225-4232.
- Maier, V.H., Melvin, D.R., Lister, C.A., Chapman, H., Gould, G.W., and Murphy, G.J. 2000. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats. *Diabetes.* 49: 618-625.
- Martienssen, R.A., and Colot, V. 2001. DNA methylation and epigenetic inheritance in plants and filamentous fungi. *Science.* 293: 1070-1073.
- MHC sequencing consortium. 1999. Complete sequence and gene map of a human major histocompatibility complex. *Nature.* 401: 921-923.

- Model, F., Adorjan, P., Olek, A., and Piepenbrock, C. 2001. Feature selection for DNA methylation based cancer classification. *Bioinformatics*. 17 Suppl. 1:S157-164.
- Monaco, J.J. (1992). A molecular model of MHC class-I-restricted antigen processing. *Immunol. Today*. 13: 173-179.
- Monk, M., Boubelik, M., and Lehnert, S. 1987. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. *Dev.* 99: 371-382.
- Moslein, G., Tester, D.J., Lindor, N.M., Honchel, R., Cunningham, J.M., French, A.J., Halling, K.C., Schwab, M., Goretzki, P., and Thibodeau, S.N. 1996. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial, and hereditary colorectal cancer. *Hum. Mol. Genet.* 5: 1245-1252.
- Munster, P.N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P.A., and Richon, V.M. 2001. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. *Cancer Res.* 61: 8492-8497.
- Myohanen, S.K., Baylin, S.B., and Herman, J.G. 1998. Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. *Cancer Res.* 58: 591-593.
- Nadler, T.S., Stoehr, J.P., Schueler, K.L., Tanimoto, G., Yandell, B.S., and Attie, A.D. 2000. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. *PNAS*. 97: 11371-11376.
- Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., and Bird, A. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature*. 393: 386-389.
- Nicholls, R.D., Saitoh, S., and Horsthemke, B. 1998. Imprinting in Prader-Willi and Angelman syndromes. *Trends Genet.* 14: 194-200.
- Nikoulina, S.E., Ciaraldi, T.P., Mudaliar, S., Mohideen, P., Carter, L., and Henry, R.R. 2000. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. *Diabetes*. 49: 263-271.
- Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., Bertheas, M.F., and Mandel, J.L. 1991. Instability of a 550-base pair segment and abnormal methylation in Fragile X Syndrome. *Science*. 252: 1097-1102.
- Okano, M., Xie, S., and Li, E. 1998a. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat. Genet.* 19: 219-20.
- Okano, M., Xie, S., and Li, E. 1998b. Dnmt2 is not required for de novo and maintenance methylation of viral DNA in embryonic stem cells. *Nucleic Acids Res.* 26: 2536-2540.
- Okano, M., Bell, D.W., Haber, D.A., and Li, E. 1999. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell*. 99: 247-257.
- Ortmann, B., Copeman, J., Lehner, P.J., Sadasivan, B., Herberg, J.A., Grandea, A.G., Riddell, S.R., Tampe, R., Spies, T., Trowsdale, J., and Cresswell, P. 1997. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. *Science*. 277: 1306-1309.
- Ottaviano, Y.L., Issa, J.P., Parl, F.F., Smith, H.S., Baylin, S.B., and Davidson, N.E. 1994. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. *Cancer Res.* 54: 2552-2555.
- Park, Y., and Kuroda, M.I. 2001. Epigenetic aspects of X-chromosome dosage compensation. *Science*. 293: 1083-1085.
- Pavliček, A., Pačes, J., Clay, O and Bernardi, G. 2002a. A compact view of isochores in the draft human genome sequence. *FEBS Letters*. 511: 165-169.
- Pavliček, A., Clay, O., Jabbari, K., Pačes, J., and Bernardi, G. 2002b. Isochore conservation between MHC regions on human chromosome 6 and mouse chromosome 17. *FEBS Letters*. 511: 175-177.
- Pfeifer, G.P., Tang, M., and Denissenko, M.F. 2000. Mutation hotspots and DNA methylation. *Curr. Top. Microbiol. Immunol.* 249: 1-19.
- Pieters, J. 1997. MHC class II restricted antigen presentation. *Curr. Opin. Immunol.* 9: 89-96.
- Pogribny, I.P., Miller, B.J., and James, S.J. 1997. Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. *Cancer Lett.* 115: 31-38.
- Pollack, Y., Stein, R., Razin, A., and Cedar, H. 1980. Methylation of foreign DNA sequences in eukaryotic cells. *Proc. Natl. Acad. Sci. USA*. 77: 6463-6467.
- Post, W.S., Goldschmidt-Clermont, P.J., Wilhide, C.C., Heldman, A.W., Sussman, M.S., Ouyang, P., Milliken, E.E., and Issa, J.P. 1999. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. *Cardiovasc. Res.* 43: 985-991.
- Pradhan, S., Talbot, D., Sha, M., Benner, J., Hornstra, L., Li, E., Jaenisch, R., and Roberts, R.J. 1997. Baculovirus-mediated expression and characterization of the full-length murine DNA methyltransferase. *Nucleic Acids Res.* 25: 4666-4673.
- Pradhan, S., Bacolla, A., Wells, R.D., and Roberts, R.J. 1999. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of de novo and maintenance methylation. *J. Biol. Chem.* 274: 33002-33010.
- Prendergast, G.C. and Ziff, E.B. 1991. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. *Science*. 251: 186-189.
- Qu, G., Dubeau, L., Narayan, A., Yu, M.C., and Ehrlich, M. 1999. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. *Mutat. Res.* 423: 91-101.
- Rada, C., and Ferguson-Smith, A.C. 2002. Epigenetics: Monoallelic expression in the immune system. *Curr. Biol.* 12: R108-R110.
- Rao, A., and Avni, O. 2000. Molecular aspects of T-cell differentiation. *Br. Med. Bull.* 56: 969-984.
- Razin, A., and Cedar, H. 1993. DNA methylation and embryogenesis. In: *DNA methylation- Molecular Biology and Biological Significance*. J.P. Jost and H.P. Saluz, eds. Basel: Birkhäuser Verlag. p. 343-357.
- Reik, W., and Maher, E.R. 1997. Imprinting in clusters: lessons from Beckwith-Wiedemann syndrome. *Trends Genet.* 13: 330-334.




- Reik, W., Dean, W., and Walter, J. 2001. Epigenetic reprogramming in mammalian development. *Science*. 293: 1089-1093.
- Rhee, I., Jair, K.W., Yen, R.W., Lengauer, C., Herman, J.G., Kinzler, K.W., Vogelstein, B., Baylin, S.B., Schuebel, K.E. 2000. CpG methylation is maintained in human cancer cells lacking DNMT1. *Nature*. 404: 1003-1007.
- Rhodes, D.A., and Trowsdale, J. 1999. Genetics and molecular genetics of the MHC. *Rev. Immunogenet.* 1: 21-31.
- Rissanen, J., Markkanen, A., Karkkainen, P., Pihlajamäki, J., Kekalainen, P., Mykkanen, L., Kuusisto, J., Karhapää, P., Niskanen, L., and Laakso, M. 2000. Sulfonyleurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. *Diabetes Care*. 23: 70-73.
- Robertson, K.D. and Wolffe, A.P. 2000. DNA methylation in health and disease. *Nat. Rev. Genet.* 1: 11-19.
- Robertson, K.D. 2001. DNA methylation, methyltransferases, and cancer. *Oncogene*. 20: 3139-3155.
- Rothenburg, S., Koch-Nolte, F., Thiele, H.G., and Haag, F. 2001. DNA methylation contributes to tissue- and allele-specific expression of the T-cell differentiation marker RT6. *Immunogenetics*. 52: 231-241.
- Russell, T.J., Schultes, L.M., and Kuban, D.J. 1972. Histocompatibility (HLA) antigens associated with psoriasis. *N. Engl. J. Med.* 287: 738-740.
- Sakai, T., Toguchida, J., Ohtani, N., Yandell, D.W., Rapaport, J.M., and Dryja, T.P. 1991. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. *Am. J. Hum. Genet.* 48: 880-888.
- Salem, C.E., Markl, I.D., Bender, C.M., Gonzales, F.A., Jones, P.A., Liang, G. 2000. PAX6 methylation and ectopic expression in human tumor cells. *Int. J. Cancer*. 87: 179-185.
- Santi, D.V., Garrett, C.E., and Barr, P.J. 1983. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. *Cell*. 33: 9-10.
- Sherr, C.J. 1996. Cancer cell cycles. *Science*. 274: 1672-1677.
- Silva, A.J., Ward, K., and White, R. 1993. Mosaic methylation in clonal tissue. *Dev. Biol.* 156: 391-398.
- Smith, U., Axelsen, M., Carvalho, E., Eliasson, B., Jansson, P.A., and Wesslau, C. 1999. Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes. *Ann. N.Y. Acad. Sci.* 892: 119-126.
- Stein, R., Gruenbaum, Y., Pollack, Y., Razin, A., and Cedar, H. 1982. Clonal inheritance of the pattern of DNA methylation in mouse cells. *Proc. Natl. Acad. Sci. USA*. 79: 61-65.
- Stephens, R., Horton, R., Humphray, S., Rowen, L., Trowsdale, J., and Beck, S. 1999. Gene organisation, sequence variation and isochore structure at the centromeric boundary of the human MHC. *J. Mol. Biol.* 291: 789-799.
- Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., and Lazar, M.A. 2001. The hormone resistin links obesity to diabetes. *Nature*. 409: 307-312.
- Subak-Sharpe, H., Burk, R.R., Crawford, L.V., Morrison, J.M., Hay, J., and Keir, H.M. 1966. An approach to evolutionary relationships of mammalian DNA viruses through analysis of the pattern of nearest neighbor base sequences. *Cold Spring Harb. Symp. Quant. Biol.* 31: 737-748.
- Takei, S., Fernandez, D., Redford, A., and Toyoda, H. 1996. Methylation status of 5'-regulatory region of tumor necrosis factor alpha gene correlates with differentiation stages of monocytes. *Biochem. Biophys. Res. Commun.* 220: 606-612.
- Tamaru, H., and Selker, E.U. 2001. A histone H3 methyltransferase controls DNA methylation in *Neurospora crassa*. *Nature*. 414: 277-283.
- Tate, P.H., and Bird, A.P. 1993. Effects of DNA methylation on DNA-binding proteins and gene expression. *Curr. Opin. Genet. Dev.* 3: 226-231.
- Temple, I.K., Gardner, R.J., Mackay, D.J., Barber, J.C., Robinson, D.O., and Shield, J.P. 2000. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. *Diabetes*. 49: 1359-1366.
- Tenzen, T., Yamagata, T., Fukagawa, T., Sugaya, K., Ando, A., Inoko, H., Gojobori, T., Fujiyama, A., Okumura, K., and Ikemura, T. 1997. Precise switching of DNA replication timing in the GC content transition area in the human major histocompatibility complex. *Mol. Cell Biol.* 17: 4043-4050.
- The International SNP Map Working Group. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature*. 409: 928-933.
- Thibodeau, S.N., French, A.J., Roche, P.C., Cunningham, J.M., Tester, D.J., Lindor, N.M., Moslein, G., Baker, S.M., Liskay, R.M., Burgart, L.J., Honchel, R., and Halling, K.C. 1996. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. *Cancer Res.* 56: 4836-4840.
- Tohgi, H., Utsugisawa, K., Nagane, Y., Yoshimura, M., Genda, Y., and Ukitsu, M. 1999. Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. *Brain Res. Mol. Brain Res.* 70: 288-292.
- Toyota, M., Ho, C., Ahuja, N., Jair, K.W., Li, Q., Ohe-Toyota, M., Baylin, S.B., and Issa, J.P. 1999. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. *Cancer Res.* 59: 2307-2312.
- Trembath, R.C., Clough, R.L., Rosbotham, J.L., Jones, A.B., Camp, R.D.R., Frodsham, A., Browne, J., Barber, R., Terwilliger, J., Lathrop, G.M., and Barker, J.N.W.N. 1997. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. *Hum. Mol. Genet.* 6: 813-820.
- Tutt Landolfi, M.M., Scollay, R., and Parnes, J.R. 1997. Specific demethylation of the CD4 gene during CD4 T lymphocyte differentiation. *Mol. Immunol.* 34: 53-61.
- Vertino, P.M., Yen, R.W., Gao, J., and Baylin, S.B. 1996. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5)-methyltransferase. *Mol. Cell Biol.* 16: 4555-4565.
- Vyse, T., and Todd, J.A. 1996. Genetic analysis of

- autoimmune disease. *Cell*. 85: 311-318.
- Wade, P.A. 2001. Methyl CpG-binding proteins and transcriptional repression. *BioEssays*. 23: 1131-1137.
- Walsh, C.P., Chaillet, J.R., and Bestor, T.H. 1998. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. *Nat. Genet.* 20: 116-117.
- Wandstrat, A., and Wakeland, E. 2001. The genetics of complex autoimmune diseases: non-MHC susceptibility genes. *Nat. Immunol.* 2: 802-809.
- Woodcock, D.M., Lawler, C.B., Lisenmeyer, M.E., Doherty, J.P., and Warren, W.D. 1997. Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon. *J. Biol. Chem.* 272: 7810-7816.
- Wu, C.-t., and Morris, J.R. 2001. Genes, genetics and epigenetics: a correspondence. *Science*. 293: 1103-1104.
- Xu, G.L., Bestor, T.H., Bourc'his, D., Hsieh, C.L., Tommerup, N., Bugge, M., Hulten, M., Qu, X., Russo, J.J., and Viegas-Pequignot, E. 1999. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature*. 402: 187-191.
- Yan, P.S., Perry, M.R., Laux, D.E., Asare, A.L., Caldwell, C.W., and Huang, T.H. 2000. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. *Clin. Cancer Res.* 6: 1432-1438.
- Yang, X., Ferguson, A.T., Nass, S.J., Phillips, D.L., Butash, K.A., Wang, S.M., Herman, J.G., and Davidson, N.E. 2000. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. *Cancer Res.* 60: 6890-6894.
- Yang, X., Phillips, D.L., Ferguson, A.T., Nelson, W.G., Herman, J.G., and Davidson, N.E. 2001. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. *Cancer Res.* 61: 7025-7029.
- Yoder, J.A., Walsh, C.P., and Bestor, T.H. 1997. Cytosine methylation and the ecology of intragenomic parasites. *Trends Genet.* 13: 335-340.
- Yoder, J.A. and Bestor, T.H. 1998. A candidate mammalian DNA methyltransferase related to pmt1p of fission yeast. *Hum. Mol. Genet.* 7: 279-284.
- Yokomori, N., Tawata, M., and Onaya, T. 1999. DNA demethylation during the differentiation of 3T3-L1 cells affects the expression of the mouse GLUT4 gene. *Diabetes*. 48: 685-690.
- Yoon, J.H., Smith, L.E., Feng, Z., Tang, M., Lee, C.S., and Pfeifer, G.P. 2001. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. *Cancer Res.* 61: 7110-7117.
- Yoshiura, K., Kanai, Y., Ochiai, A., Shimoyama, Y., Sugimura, T., and Hirohashi, S. 1995. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. *Proc. Natl. Acad. Sci. USA*. 92: 7416-7419.
- Zion, M., Ben Yehuda, D., Avraham, A., Cohen, O., Wetzler, M., Melloul, D., and Ben Neriah, Y. 1994. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. *Proc. Natl. Acad. Sci. USA*. 91: 10722-10726.




Further Reading

Caister Academic Press is a leading academic publisher of advanced texts in microbiology, molecular biology and medical research. Full details of all our publications at [caister.com](http://www.caister.com)

- **MALDI-TOF Mass Spectrometry in Microbiology**
Edited by: M Kostrzewa, S Schubert (2016)
www.caister.com/malдитof
- ***Aspergillus* and *Penicillium* in the Post-genomic Era**
Edited by: RP Vries, IB Gelber, MR Andersen (2016)
www.caister.com/aspergillus2
- **The Bacteriocins: Current Knowledge and Future Prospects**
Edited by: RL Dorit, SM Roy, MA Riley (2016)
www.caister.com/bacteriocins
- **Omics in Plant Disease Resistance**
Edited by: V Bhadauria (2016)
www.caister.com/opdr
- **Acidophiles: Life in Extremely Acidic Environments**
Edited by: R Quatrini, DB Johnson (2016)
www.caister.com/acidophiles
- **Climate Change and Microbial Ecology: Current Research and Future Trends**
Edited by: J Marxsen (2016)
www.caister.com/climate
- **Biofilms in Bioremediation: Current Research and Emerging Technologies**
Edited by: G Lear (2016)
www.caister.com/biorem
- **Microalgae: Current Research and Applications**
Edited by: MN Tsaloglou (2016)
www.caister.com/microalgae
- **Gas Plasma Sterilization in Microbiology: Theory, Applications, Pitfalls and New Perspectives**
Edited by: H Shintani, A Sakudo (2016)
www.caister.com/gasplasma
- **Virus Evolution: Current Research and Future Directions**
Edited by: SC Weaver, M Denison, M Roossinck, et al. (2016)
www.caister.com/virusevol
- **Arboviruses: Molecular Biology, Evolution and Control**
Edited by: N Vasilakis, DJ Gubler (2016)
www.caister.com/arbo
- ***Shigella*: Molecular and Cellular Biology**
Edited by: WD Picking, WL Picking (2016)
www.caister.com/shigella
- **Aquatic Biofilms: Ecology, Water Quality and Wastewater Treatment**
Edited by: AM Romani, H Guasch, MD Balaguer (2016)
www.caister.com/aquaticbiofilms
- **Alphaviruses: Current Biology**
Edited by: S Mahalingam, L Herrero, B Herring (2016)
www.caister.com/alpha
- **Thermophilic Microorganisms**
Edited by: F Li (2015)
www.caister.com/thermophile



- **Flow Cytometry in Microbiology: Technology and Applications**
Edited by: MG Wilkinson (2015)
www.caister.com/flow
- **Probiotics and Prebiotics: Current Research and Future Trends**
Edited by: K Venema, AP Carmo (2015)
www.caister.com/probiotics
- **Epigenetics: Current Research and Emerging Trends**
Edited by: BP Chadwick (2015)
www.caister.com/epigenetics2015
- ***Corynebacterium glutamicum*: From Systems Biology to Biotechnological Applications**
Edited by: A Burkovski (2015)
www.caister.com/cory2
- **Advanced Vaccine Research Methods for the Decade of Vaccines**
Edited by: F Bagnoli, R Rappuoli (2015)
www.caister.com/vaccines
- **Antifungals: From Genomics to Resistance and the Development of Novel Agents**
Edited by: AT Coste, P Vandeputte (2015)
www.caister.com/antifungals
- **Bacteria-Plant Interactions: Advanced Research and Future Trends**
Edited by: J Murillo, BA Vinatzer, RW Jackson, et al. (2015)
www.caister.com/bacteria-plant
- ***Aeromonas***
Edited by: J Graf (2015)
www.caister.com/aeromonas
- **Antibiotics: Current Innovations and Future Trends**
Edited by: S Sánchez, AL Demain (2015)
www.caister.com/antibiotics
- ***Leishmania*: Current Biology and Control**
Edited by: S Adak, R Datta (2015)
www.caister.com/leish2
- ***Acanthamoeba*: Biology and Pathogenesis (2nd edition)**
Author: NA Khan (2015)
www.caister.com/acanthamoeba2
- **Microarrays: Current Technology, Innovations and Applications**
Edited by: Z He (2014)
www.caister.com/microarrays2
- **Metagenomics of the Microbial Nitrogen Cycle: Theory, Methods and Applications**
Edited by: D Marco (2014)
www.caister.com/n2



Order from caister.com/order